SCM
CAPR icon

SB Capital Management’s Capricor Therapeutics CAPR Stock Holding History

SB Capital Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$11.5M Buy
+400,001
New +$5.22M 4.23% 5

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SB Capital Management's CAPR Position: Q4 2025 in Review

SB Capital Management opened a new position in Capricor Therapeutics (CAPR) in Q4 2025: 400,001 shares worth $11.5M. The stake represents 4.23% of the portfolio and ranks #5 among its holdings.

132 funds tracked by Wall St. Rank hold CAPR as of Q4 2025.

  • SB Capital Management held 400,001 shares of Capricor Therapeutics worth $11.5M as of Q4 2025.
  • Capricor Therapeutics was a new SB Capital Management position in Q4 2025.
  • Capricor Therapeutics made up 4.23% of SB Capital Management's portfolio in Q4 2025, its #5 holding.
  • 132 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q4 2025.

Based on SB Capital Management's 13F filing for Q4 2025, filed 20 Feb 2026.